Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T Cell-Depleted Hematopoietic Stem Cell Transplantation-University of Wisconsin, Madison-lymphoma
- Development stage
- Unknown
- Lead developer
- University of Wisconsin–Madison
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
A specialized allogeneic hematopoietic stem cell transplantation (HSCT) procedure developed at the University of Wisconsin, Madison, for the treatment of relapsed lymphoma. This approach utilizes graft engineering to selectively deplete TCR-α/β+ T cells and CD19+ B cells from peripheral blood stem cell grafts obtained from haploidentical (half-matched) donors. By removing αβ T cells, which are the primary mediators of graft-versus-host disease (GVHD), while preserving γδ T cells and natural killer (NK) cells, the procedure aims to reduce the risk of GVHD and improve safety without requiring intensive pharmacological immunosuppression. The depletion of CD19+ B cells is further intended to prevent post-transplant Epstein-Barr virus (EBV)-associated lymphoproliferative disorders. This cell therapy modality is designed to provide a potent graft-versus-lymphoma effect while facilitating rapid hematopoietic engraftment.
- Other names
- TCR-α/β and CD19 Depleted Hematopoietic Stem Cell TransplantationTCR alpha-beta/CD19-depleted HSCTCliniMACS TCR-α/β and CD19 Depleted Stem Cell Grafts
Beyond the preview
Go deeper on T Cell-Depleted Hematopoietic Stem Cell Transplantation-University of Wisconsin, Madison-lymphoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T Cell-Depleted Hematopoietic Stem Cell Transplantation-University of Wisconsin, Madison-lymphoma.